• Japanese
  • Korean
  • Chinese
Cover Image

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Abstract

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Insulin Degludec sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Insulin Degludec
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Insulin Degludec including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Insulin Degludec in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 Diabetes 5
  • 2.2 Epidemiology 5
    • 2.2.1 Prevalence 5
    • 2.2.2 Mortality 7
  • 2.3 Etiology and Risk Factors 9
    • 2.3.1 Obesity 9
    • 2.3.2 Sedentary Lifestyle 9
    • 2.3.3 Family History and Genetics 9
    • 2.3.4 Ethnicity 9
    • 2.3.5 Old Age 9
  • 2.4 Economic Impact of Diabetes 9
  • 2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

  • 3.1 Type 2 Diabetes Market 12
  • 3.2 Type 2 Diabetes Market Forecasts and CAGR 13
  • 3.3 Type 2 Diabetes Market: Drivers and Restraints 14
    • 3.3.1 Drivers 14
    • 3.3.2 Restraints 15

4 Classification of Diabetes 16

  • 4.1 Types of Diabetes 16
    • 4.1.1 Type1 Diabetes 16
    • 4.1.2 Type 2 Diabetes 16
    • 4.1.3 Gestational Diabetes 16
  • 4.2 Diabetes Complications 16
    • 4.2.1 Cardiovascular Disease 16
    • 4.2.2 Nephropathy 17
    • 4.2.3 Neuropathy 17
    • 4.2.4 Amputation 17
    • 4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

  • 6.1 Insulin 19
  • 6.2 Oral Medications 19
    • 6.2.1 Sulfonylureas (SUR) 19
    • 6.2.2 Biguanides (BGDs) 19
    • 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
    • 6.2.4 Meglitinides 21
    • 6.2.5 Thiazolidinediones (TZDs) 22
    • 6.2.6 Dipeptidyl Peptidase IV (DPP-4) Inhibitors 23
    • 6.2.7 Oral Combination Therapy 23
  • 6.3 Other Injectionable Medications 24
    • 6.3.1 Pramlintide 24
    • 6.3.2 Exenatide 24
  • 6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Insulin Degludec 26

  • 7.1 Introduction 26
  • 7.2 Mechanism of Action 26
  • 7.3 Clinical Studies 26
  • 7.4 Factors Affecting Sales of Insulin Degludec 26
    • 7.4.1 Novel Ultra Long-Acting Insulin 26
    • 7.4.2 Growing Insulin Market 27
    • 7.4.3 Higher Dosing Convenience 27
    • 7.4.4 Reduced Incidence of Hypoglycemia 27
  • 7.5 Drug Evaluation 27
    • 7.5.1 Drug Risk Benefit Score 27
    • 7.5.2 Intensity of Competition 28
  • 7.6 Sales Forecasts 28
    • 7.6.1 Target Patient Pool 29
    • 7.6.2 Dosing 29
    • 7.6.3 Annual Cost of Therapy 29
    • 7.6.4 Market Penetration 29
    • 7.6.5 Sales Projections of Insulin Degludec 30

8 Diabetes Market: Appendix 39

  • 8.1 Market Definitions 39
  • 8.2 List of Abberiviations 39
  • 8.3 Research Methodology 39
    • 8.3.1 Coverage 40
    • 8.3.2 Secondary Research 40
    • 8.3.3 Forecasting 40
    • 8.3.4 Number of patients approved to take the drug 40
    • 8.3.5 Net Penetration of Drug 41
    • 8.3.6 Net Annual Dosing 41
    • 8.3.7 Annual Cost of Therapy 41
  • 8.4 Drug Sales Estimates Model 41
  • 8.5 Contact Us 41
  • 8.6 Disclaimer 42
  • 8.7 Sources 42

List of Tables

1.1 List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($m), 2010 10
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
  • Table 8: Diabetes Drugs Evolution 18
  • Table 9: Drug Risk Benefit Score of Insulin Degludec 27
  • Table 10: Types of Insulin 28
  • Table 11: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020 30
  • Table 12: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020 31
  • Table 13: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020 32
  • Table 14: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020 33
  • Table 15: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020 34
  • Table 16: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020 35
  • Table 17: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020 36
  • Table 18: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020 37

List of Figures

1.2 List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010 6
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030 6
  • Figure 3: Diabetes, World, Mortality, 2010 7
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 13
  • Figure 6: Mechanism of Action of Sulfonylureas 19
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
  • Figure 9: Mechanism of Action of Thiazolidinediones 22
  • Figure 10: Mechanism of Action of DPP IV Inhibitors 23
  • Figure 11: Type 2 Diabetes, Global, Branded Market Share By Class (%), 2010 25
  • Figure 12: Insulin Degludec, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013-2020 30
  • Figure 13: Insulin Degludec, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013-2020 31
  • Figure 14: Insulin Degludec, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013-2020 32
  • Figure 15: Insulin Degludec, Type 2 Diabetes, France, Sales Forecasts ($m), 2013-2020 33
  • Figure 16: Insulin Degludec, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013-2020 34
  • Figure 17: Insulin Degludec, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013-2020 35
  • Figure 18: Insulin Degludec, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013-2020 36
  • Figure 19: Insulin Degludec, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2014-2020 37
  • Figure 20: Insulin Degludec, Type 2 Diabetes, Sales Distribution by Country (%), 2020 38
  • Figure 21: Patients Approved for the Drug 41
Show More
Pricing